The Role of Glycocalyx and Caveolae in Vascular Homeostasis and Diseases

Simone Regina Potje, Tiago Dal-Cin Paula, Michele Paulo and Lusiane Maria Bendhack*

Faculty of Pharmaceutical Sciences of Ribeirão Preto, University of São Paulo, Ribeirão Preto, Brazil

This review highlights recent findings about the role that endothelial glycocalyx and caveolae play in vascular homeostasis. We describe the structure, synthesis, and function of glycocalyx and caveolae in vascular cells under physiological and pathophysiological conditions. Special focus will be given in glycocalyx and caveolae that are associated with impaired production of nitric oxide (NO) and generation of reactive oxygen species (ROS). Such alterations could contribute to the development of cardiovascular diseases, such as atherosclerosis, and hypertension.

Keywords: glycocalyx, caveolae, vascular tone, ROS, hypertension, atherosclerosis, endothelial cells, eNOS

INTRODUCTION

The role that endothelium plays in modulating the vascular tone includes the synthesis and release of several vasoactive substances, especially the vasodilator nitric oxide (NO) (Cahill and Redmond, 2016). Endothelial NO synthase (eNOS) is responsible for the synthesis of most of the NO that is produced in endothelial cells (ECs) (Zhao et al., 2015). eNOS is localized on domains named caveolae, which are spread over the entire ECs surface (Shaul, 2003). The glycocalyx is a polysaccharide-rich layer, which underlies mechano-transduction and mediates the physiological activation of NO synthesis by shear stress (Pahakis et al., 2007). More specifically, the glycocalyx components transform mechanical signals into biochemical signals, to activate eNOS (Florian et al., 2003; Pahakis et al., 2007), thereby contributing to vascular homeostasis (Alphonsus and Rodseth, 2014).

Shedding of glycocalyx and changes in the structure of caveolae decreases eNOS activity, which reduces NO bioavailability and generates reactive oxygen species (ROS) (Kumagai et al., 2009; Potje et al., 2019). Both consequences are associated with cardiovascular diseases such as atherosclerosis and hypertension. Therefore, the organization and function of glycocalyx and caveolae might be altered in atherosclerosis and hypertension, which results in release of deleterious ROS that contribute to these pathological conditions.

This review aims to highlight recent findings about the activation of glycocalyx and caveolar enzymes that participate in the synthesis and release of NO and ROS and alterations that could impair the proper function of glycocalyx and caveolae in pathological conditions like atherosclerosis and hypertension.
**STRUCTURE AND SYNTHESIS OF ENDOTHELIAL GLYCOCALYX**

As reviewed by different groups, the endothelial glycocalyx is mainly composed of glycosaminoglycans, proteoglycans, and glycoproteins. Heparan sulfate, chondroitin sulfate, and hyaluronic acid chains constitute glycosaminoglycans. Proteoglycans include core protein families such as perlecan, syndecans-1, -2, -3, -4, and glypican-1. Lastly, glycoproteins consist of sialic acid oligosaccharides (Uchimido et al., 2019; Möckl, 2020).

Heparan sulfate is the predominant constituent (from 50 to 90%) of glycocalyx (Reitsma et al., 2007). The syndecan family can contain three to eight potential heparan sulfate attachment sites depending on the specific syndecan member. These sites are located close to the syndecan NH₂-terminal ectodomain or adjacent to the transmembrane domain near the syndecan COOH terminal. Glypican-1 is the only proteoglycan that is expressed exclusively in ECs. It binds specifically to the heparan sulfate chain and is localized in lipid rafts (caveolae) through a C-terminal glycosylphosphatidylinositol (GPI) anchor (Uchimido et al., 2019; Möckl, 2020).

 Biosynthesis of glycosaminoglycans is a complex process that is initiated by chain polymerization and which depends on various stepwise reactions like sulfation and epimerization. This process happens in many cellular components including endoplasmic reticulum and Golgi apparatus, which are responsible for the secretory pathway (Uchimido et al., 2019; Möckl, 2020). On the other hand, hyaluronic acid is directly secreted into the extracellular space by playing a proangiogenic role (Fuster and Wang, 2010). 6-O-sulfation of heparan sulfate is an essential regulator of vascular morphogenesis in zebrafish (Chen et al., 2005). In addition, decreased heparan sulfate N-sulfation impairs recruitment of pericytes and development of vasculature in N-deacetylase/N-sulfotransferase (Ndst)-1 knockout mice (Abramsson et al., 2005). Moreover, complete loss of heparan sulfate chains in mural cells causes embryonic death in the late stages of vascular morphogenesis and stability (Stenzel et al., 2009). In this way, glycocalyx contributes to angiogenesis process.

Antithrombin III is the main anticoagulant molecule that can bind to specific sites of heparan sulfate; it also inhibits coagulant factors and inactivates factors IX and X (Shimada et al., 1991; Quinsey et al., 2004). Likewise, tissue factor pathway inhibitor (TFPI) can also bind to heparan sulfates and block the initial steps of blood coagulation by inhibiting factors VIIa and Xa (Kato, 2002). Additionally, dermathan sulfate in glycocalyx can activate heparin cofactor II, which inhibits thrombin (Tovar et al., 2005). Furthermore, degradation of endothelial glycocalyx induced by hyperglycemia activates coagulation in healthy subjects (Nieuwdorp et al., 2006b). Therefore, glycocalyx has anticoagulant and antithrombotic effects.

The glycocalyx layer has consistency and anti-adhesive character, promoting resistance to penetration of circulating leukocytes and preventing leukocyte-endothelial adhesion in vascular smooth muscle cells (VSMCs). Besides, degradation of the glycocalyx layer provoked by heparitinase in mouse cremaster venules increases leukocyte adhesion in a dose-dependent manner (Constantinescu et al., 2003). In addition, enzymatic degradation of glycocalyx promoted increased of ICAM-1 activity in response to flow and leukocyte adhesion (McDonald et al., 2016). Moreover, endotoxemia stimulated in mice by tumor necrosis factor-α (TNF-α) rapidly degrades pulmonary microvascular glycocalyx, which contributes to neutrophil adhesion (Schmidt et al., 2012). Consequently, the damage of glycocalyx favors the adherence of leukocyte on the ECs.

Tumor necrosis factor-α treatment increases porosity and permeation due to glycocalyx shedding with enhanced intraluminal volume (Henry and Duling, 2000). Patients with type 1 diabetes show glycocalyx damage in sublingual capillaries, which is associated with microalbuminuria (Nieuwdorp et al., 2006a). Furthermore, degradation of heparan sulfate by heparanase promotes injury in porcine aortic ECs, which was associated to apoptosis and cell death (Han et al., 2005). Thus, glycocalyx works as a barrier and filter, besides protecting vascular cells.

Shear stress on ECs is a frictional force (mechanical signals) per unit area created by laminar blood flow (Pohl et al., 1986). Heparan sulfate is important to detect the direction of shear stress because degradation of this substance prevents shear-stress-induced directional migration of ECs and inhibits recruitment of phosphorylated focal adhesion kinase in the flow direction (Moon et al., 2005). Nevertheless, remodeling of glycocalyx in response to short and long periods of shear stress has been reported (Liu et al., 2016). Moreover, reorganization of actin cytoskeleton and focal adhesions in response to fluid shear stress has been shown in rat fat-pad ECs in various flow media (Thi et al., 2004). Similarly, changes in the actin cytoskeleton and caveolae have been demonstrated after long-term shear stress (24 h), which also redistributes and restores heparan sulfate, syndecan-1, and glypican-1 on the apical surface of ECs (Zeng and Tarbell, 2014). In this way, the actin cytoskeleton contributes to the structural stability of glycocalyx under shear stress (Li and Wang, 2018).

Mechano-transduction is the conversion of mechanical signals induced by shear stress into biochemical signals inside ECs (Dabagh et al., 2017). Endothelial glycocalyx has been described as the primary sensor activating the mecano-transduction process, creating an immediate response to shear stress stimulus and producing NO. Removing heparan sulfate and other
glycocalyx components through a selective enzyme that degrades endothelial glycocalyx constituents blocks shear-induced NO production in ECs (Florian et al., 2003; Pahakis et al., 2007; Yen et al., 2015; Dragovich et al., 2016). Furthermore, NO production mediated by glycocalyx is associated with calcium influx mediated by endothelial transient receptor potential (TRP) channels. Under stimulation, the proteoglycans promote tension in the lipid bilayer, which spreads through ECs due to its interaction with cytoskeleton, and then both proteoglycans and cytokines may activate a diversity of mechanically sensitive ion channels, such as TRP channels (Dragovich et al., 2016). In addition, reduced NO production induced by flow has been reported in isolated canine femoral arteries treated with hyaluronidase, which degrades the hyaluronic acid GAG (Mochizuki et al., 2003). These results show that intact glycocalyx, mainly heparan sulfate chains, are needed to activate eNOS and thus produce NO.

Glypican-1 seems to be the main heparan sulfate proteoglycan that is associated with NO production, along with eNOS, both resides in caveolae. First, glypican-1 knockdown blocks eNOS activation under shear stress stimulus (Ebong et al., 2014). Additionally, glypican-1 removal significantly suppresses eNOS activation mediated by several steady shear stress magnitudes (Zeng and Liu, 2016). Besides that, atomic force microscopy (AFM) selectively applied on glypican-1 for a limited time significantly increases NO production, whereas pulling on syndecan-1, CD44, and hyaluronic acid does not change NO concentration (Bartsch et al., 2017). Furthermore, disturbed flow (DF) reduces caveolin-1 (Cav-1) expression and impairs its co-localization with eNOS, consequently reducing eNOS phosphorylation at Serine1177 (Harding et al., 2018). Taken together, these results indicate that glypican-1 is a primary mechano-sensor for shear stress-induced NO production, and that the glypican-1-caveolae-eNOS-NO pathway is essential for vascular tone maintenance.

**FORMATION OF CAVEOLAE**

Lipid rafts (also known as lipid microdomains) and caveolae are domains of the plasma membrane that share the same composition, such as cholesterol, sphingolipids, and glycosyl-phosphatidylinositol GPI-anchored proteins. However, the caveolae structure is an invagination at the membrane. On the other hand, lipids rafts are flat areas of the membrane (Bieberich, 2018). Caveolae were first described in the 1950s by using an electron microscope. Due to lack of experimental approaches and technologies, the caveolar functions remained mostly unclear until the 1990s (Anderson, 1998). Now, caveolae are defined as 60–80-nm-wide pits in the plasma membrane that contain oligomeric caveolin (Parton and Simons, 2007). Caveolae are predominantly expressed in vascular ECs, but they are also present in VSMCs (Gratton et al., 2004). Molecular understanding of caveolar formation is advancing rapidly, and we now know that sculpting the membrane to generate the characteristic bulb-shaped caveolar pit involves coordinated action of integral membrane proteins and peripheral membrane coat proteins in a process that depends on their multiple interactions with membrane lipids (Parton et al., 2018).

Three mammalian caveolins exist: Cav-1, Cav-2, and Cav-3. Cav-1 and Cav-2 are generally expressed together in different types of cells other than muscle cells, whereas Cav-3 is predominantly expressed in muscle cells (Razani and Lisanti, 2001). Some cells, including smooth muscle cells and cardiomyocytes, can express Cav-1, Cav-2, and Cav-3, (Head et al., 2006; Robenek et al., 2008). Each caveola has estimated 140–150 Cav-1 molecules (Pelkmans and Zerial, 2005). Cav-1 loss results in complete absence of caveoleae (Drab et al., 2001). Moreover, Cav-1 expression in cells without caveoleae causes caveoleae to form (Vogel et al., 2019). Therefore, Cav-1 is crucial for caveolar formation.

Identifying the family of cytoplasmic proteins that cooperatively work with caveolins for caveolar formation and function has expanded our understanding of caveolar biology. Liu et al. (2008) described that Cavins are cytoplasmic proteins with amino-terminal coiled-coil domains that play a role as protein component of caveolae, where they form large heteromeric complexes that are recruited by caveolins in cells expressing caveolae (Bastiani et al., 2009). The Cavin family includes Cavin-1 (also known as polymerase I and transcript release factor, PTRF), Cavin-2 (SDPR, serum deprivation response protein), Cavin-3 (also known as related gene product that binds to c-kinase - SRBC), and Cavin-4 (also known as muscle-restricted coiled-coil protein, MURC). Cavin knockout mice are viable, but they present a lipo dystrophic phenotype with high triglyceride levels, glucose intolerance, and hyperinsulinemia (Liu et al., 2008). In addition, caveolae are completely absent in Cavin knockout mice in specific tissues like lung epithelium, intestinal smooth muscle, skeletal muscle, and ECs. In this way, formation of caveolae requires Cavin-1 (Liu et al., 2008). Cavin-2 and Cavin-3 have been identified as protein kinase C (PKC) substrates and have been suggested to target PKC for caveolae. Cavin-2 has been associated with caveolar membrane curvature, and Cavin-3 affects formation of caveolar endocytic carriers (Hill et al., 2008). Cavin-4, which is predominantly expressed in cardiac and skeletal muscles, has been related to myogenesis and muscle hypertrophy via RHOA–RHO-associated kinase (ROCK), ERK1, and ERK2, as well as to regulation of atrial natriuretic peptide transcription in cardiac muscle (Ogata et al., 2008; Bastiani et al., 2009).

After trafficking to the plasma membrane, caveolin oligomers are stabilized by the complex of Cavins (Hayer et al., 2010). Lipids and/or membrane lipid order may also be important for this interaction. The four members of the Cavin family bind to phosphatidyserine, which is abundant on the cytoplasmic face of the plasma membrane, particularly in areas that are rich in caveolae (Fairn et al., 2011). Cav-1 peptides can generate phosphatidyserine domains in liposomes, so membrane lipid reorganization by caveolins might also contribute to a stable interaction in the plasma membrane (Wanaski et al., 2003). In this way, Cavins and caveolins preserve the stable coat around the bulb of caveolae (Hill et al., 2008). Additionally, a protein called Eps15 homology domain protein 2 (EHD2) is involved in mediating caveolar stabilization in the plasma.
enzymes such as eNOS are specifically enriched in caveolae in caveolae have a role in Ca$^{2+}$ release that has been postulated to be the preferred site of Ca$^{2+}$ entry in response to Ca$^{2+}$ depletion (Shaw et al., 2006). These observations suggest that membrane rafts and caveolae have a role in Ca$^{2+}$ signaling.

According to Durr et al. (2004), various proteins like G-protein-coupled receptor (GPCR) and downstream signaling enzymes such as eNOS are specifically enriched in caveolae in ECs. Additionally, caveolae contribute to GPCR desensitization and internalization (Chini and Parenti, 2004). For example, the stimulation with angiotensin II (Ang II) promotes rapid translocation of AT$_1$ receptor (AT$_1$R) to caveolae, then AT$_1$R bind to Cav-1, which delays AT$_1$R reactivation after prolonged stimulus with Ang II (Ishizaka et al., 1998; Czikora et al., 2015).

**CONTRIBUTION OF ENOS AND CAV-1 TO NO GENERATION**

Controlling eNOS activation falls under a complex regulatory mechanism that includes tonic inhibitory interaction with Cav-1 (Ju et al., 1997) and post-translational modifications like myristoylation, palmitoylation, phosphorylation, and stimulatory responses, to raise intracellular Ca$^{2+}$ concentrations (Sessa, 2004).

Endothelial NO synthase remains associated with Cav-1, which is the major component of caveolae. eNOS requires palmitoylation and myristoylation to be targeted to the caveolar microdomains. The interactions between Cav-1 and eNOS have been shown to regulate NO release negatively (Grayson et al., 2012). In this way, Cav-1 over-expression decreases basal NO production in a "control" cellular state. Moreover, under agonist activation, eNOS translocates away from caveolae, thereby removing tonic Cav-1 inhibition (Frank et al., 2003). Feron et al. (1998) identified that, after agonist-dependent eNOS activation, removal of tonic inhibition between eNOS and Cav-1 coincides with de-palmitoylation concomitant with eNOS translocation to the non-caveolar fraction, which indicates increased NO biosynthesis. Conversely, when eNOS returns to the membrane/caveolae, it is re-palmitoylated, and its inhibitory interaction with Cav-1/eNOS is reasserted.

A model for activation of eNOS bound to Cav-1 considers that, under stimulation with Ca$^{2+}$-mobilizing agonists, the inhibitory scaffold of Cav-1 is relieved via calcium-regulated binding of calmodulin and Hsp90 to displace eNOS from Cav-1, thus allowing efficient NO production (Sessa, 2004). Evidence supporting the inhibition model includes enhanced NO-dependent vascular function in blood vessels from Cav-1 knockout mice and increased NO production in ECs isolated from Cav-1 knockout mice, an effect that is rescued by Cav-1 reintroduction (Drab et al., 2001; Razani et al., 2001; Murata et al., 2007). Besides, transduction of cells or blood vessels with Cavitatin, a synthetic cell permeable Cav-1 CSD peptide, reduces NO release and inflammation in vivo (Bucci et al., 2006). Alanine scanning of this scaffolding region demonstrated that the threonine residues 90 and 91 (T90, T91) and phenylalanine 92 (F92) underlie eNOS inhibition. This is supported by lack of eNOS inhibition by the F92A–Cav-1 mutant in reconstituted cells and a Cavitatin-derived peptide with the T90/91 and F92 substitutions (a peptide called Cavnoxin) as revealed by studies in vitro and in vivo (Bernatchez et al., 2005).

Sowa (2012) showed that Cav-1 in caveolae but not in lipid rafts can inhibit eNOS under basal conditions. Although Cav-1 in caveolae keeps eNOS inactive, the specific localization of Cav-1 in this cell organelle is necessary for its activation
In addition, Cav-1/eNOS interaction is necessary to prevent inadequate NO production under basal conditions and to facilitate integration of extracellular stimuli with intracellular NO signals (Rath et al., 2009).

**OXIDATIVE STRESS IN CARDIOVASCULAR DISEASES**

Reactive oxygen species are a group of heterogeneous molecules that are characterized by highly reactive oxygen atoms, short half-life, and strong capacity to engage in oxidation reactions (Vara and Pula, 2014). They are essential for homeostasis of the cardiovascular system and play a role in signaling pathways in different cells. An imbalance in antioxidant and oxidant systems promotes ROS overproduction, which culminates in oxidative stress, a well-known and important hallmark of cardiovascular diseases (Panth et al., 2016). When ROS levels overtake the cellular defenses, protein, lipids, and DNA can undergo oxidation, which can lead to cellular damage, tissue injury, and inflammation (Sen et al., 2018). ROS are produced by distinct enzymatic sources like xantine oxidase, NADPH-oxidase (NOX), cyclooxygenase (COX), lipooxygenase (LOX), monomeric eNOS (uncoupled eNOS), myeloperoxidase, and also by the respiratory chain in mitochondria (Vara and Pula, 2014; Sena et al., 2018). The chemical species anion superoxide (O$_2^-$), peroxynitrite (ONOO$^-$), hydrogen peroxide (H$_2$O$_2$), and hydroxyl radical (•OH) underlie deleterious effects of oxidative stress. However, ROS present not only deleterious, but also physiological effects on vascular tone in VSMCs and on ECs motility, proliferation, and permeability (Vara and Pula, 2014).

For example, O$_2^-$ induces protein kinase-dependent contraction in VSMCs under high pressure (Ungvari et al., 2003), whereas H$_2$O$_2$ upregulates vascular endothelial growth factor receptor 2 (González-Pacheco et al., 2006).

Each oxidant chemical species can be removed from the cellular environment by different enzymes that make up the antioxidant system, including superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase, thioredoxin, peroxiredoxin, and glutathione transferase. SOD dismutates O$_2^-$ in H$_2$O$_2$, which is broken down into O$_2$ and H$_2$O by CAT and glutathione peroxidase (Birben et al., 2012). The radical species can also activate the nuclear factor erythroid 2-like 2 (Nrf-2), a transcription factor that is involved in the dynamic regulation of the antioxidant system, thereby activating the expression of promoters containing the antioxidant response element (Satta et al., 2017).

In the vascular system, both ECs and VSMCs can be either producers or targets of ROS. H$_2$O$_2$ is produced by NOX4 in ECs (Burtenshaw et al., 2019) and it can elicit different responses in VSMCs depending on its concentration (Gil-Longo and González-Vázquez, 2005). Importantly, H$_2$O$_2$ seems to be increased in aortas from hypertensive rats under stimulus (Silva et al., 2013). O$_2^-$ can be produced by NOX isoforms expressed in the membrane and in the intracellular compartment of ECs (Li and Shah, 2002) and by mitochondria, which are considered the major source of O$_2^-$ in ECs (Li et al., 2016). In cardiovascular diseases, O$_2^-$ significantly contributes to endothelial dysfunction because it rapidly reacts with NO, to produce the highly oxidizing ONOO$^-$ (Radi, 2018), thus decreasing NO bioavailability. In addition, ROS can induce conversion of ECs to myofibroblasts, losing its endothelial properties (Montorfonaro et al., 2014).

Endothelial dysfunction is characterized by reduced endothelial response to different stimuli that release NO and other chemical mediators related to vasodilation or higher levels of endothelial chemical mediators associated with vasoconstriction (Vanhoutte et al., 2017). Therefore, exacerbated oxidative stress in ECs modifies the response of endothelial NO, and ROS produced by ECs can induce response in VSMCs.

In VSMCs, ROS production is mediated especially by NOX1 and NOX4 and produces O$_2^-$ and H$_2$O$_2$, respectively (Burtenshaw et al., 2019). Increased ROS in VSMCs is a common feature of different models of hypertension such as AngII-infused model (Rajagopalan et al., 1996; Zhou et al., 2020), spontaneously hypertensive rats (SHR) (Gratoni et al., 2019), renovascular hypertension (2K-1C) (Castro et al., 2012; Oliveira-Paula et al., 2016), and Doca-Salt rats (Amaral et al., 2015). Physiologically, contraction mediated by activation of α-1 adrenoceptors can partially depend on O$_2^-$ (Tsai and Jiang, 2010). The hypercontractile profile of VSMCs of hypertensive rats seems to depend on ROS production (Camargo et al., 2018). Additionally, ROS produced by VSMCs can reduce NO bioavailability.

**OXIDATIVE STRESS IN CAVEOLAE AND CAVEOLIN**

Cav-1 seems to be involved in the process involving ROS as target or controlling ROS production. Oxidative stress mediated by H$_2$O$_2$ degrades Cav-1 in skeletal muscle cells (Mougeolle et al., 2015). H$_2$O$_2$ is increased in aorta of renal hypertensive rats (Silva et al., 2013), and the total number of caveolae is reduced in aorta of hypertensive rats (Rodrigues et al., 2010; Potje et al., 2019).

Thus, H$_2$O$_2$ overproduction can be important to reduce Cav-1 levels and to disrupt the function of caveolae in hypertension.

Cav-1 is related to the AngII (AT1) receptor because the AT1-R-caveolin complex requires an intact caveolin scaffolding domain, but not co-localization in the caveolae (Wyse et al., 2003). Exposure to the agonist Ang II changes the Cav-1 levels in VSMCs (Ishizaka et al., 1998). Interestingly, Cav-1 loss increases NOX activity and ROS production in VSMCs (Zuo et al., 2005; Chen et al., 2014). In contrast, Cav-1 deletion can prevent remodeling induced by Ang II (Forrester et al., 2017). As stated before, Nrf-2 is an important element that controls the levels of antioxidant enzymes. ROS can activate Nrf-2 migration to the nucleus, thereby raising the expression of antioxidant enzymes and leading to detoxification of the cells (Satta et al., 2017). Curiously, Cav-1 seems to repress this migration given that Cav-1 knockout mice constantly present high Nrf2 levels in nucleus (Volonte et al., 2013). Changes in Nrf2 levels can alter the physiology of normal cells due to upstream and downstream of molecules that are associated with a defective Nrf2 signaling system (Satta et al., 2017). Thus, most of the common
FIGURE 1 | Schematic representation of caveola and glycocalyx proteins in endothelial cells (ECs) under non-pathological and pathological conditions. In non-pathological conditions, the glycocalyx proteins are intact and the coupled eNOS (dimeric form) is inactivated linked to Cav-1 protein. The eNOS is activated by shear stress mediated by Glypican-1 mechano-transduction as well as increase in calcium levels. The NO bioavailability can protect the cardiovascular system, and ROS produced by different sources stimulates the antioxidant system that also protects the cells of oxidative damage. In pathological conditions, the rise in ROS production mediated by pro-oxidant molecules as Ang II overtakes the antioxidant defenses. The ROS can degrade Cav-1, the eNOS is uncoupled (monomeric) that can be source of ROS, and NO bioavailability is reduced. ROS also stimulates the sheddases activity clivating the heparan sulfate from glypican and syndecan losing its ability to induce eNOS activation mediated by shear stress. Those frames with low NO levels can potentiate the cardiovascular risks.

features of hypertensive vessels, e.g., endothelial dysfunction and hypercontractile VSMCs, can result from ROS actions, Cav-1 levels, and caveolar functions.

EFFECT OF ROS ON ENDOTHELIAL GLYCOCALYX DEGRADATION

Specific enzymes, named sheddases, as well as metalloproteinases (MMPs), heparanase, and hyaluronidase degrade glycocalyx. Sheddases are activated by pro-inflammatory cytokines such as TNFα (Ramnath et al., 2014), interleukin-1beta (Haywood-Watson et al., 2011), interleukin-6, and interleukin-8 and also by shear stress, hypoxia, and ROS (Lipowsky and Lescanic, 2013). In this review, we focus only on how ROS affect endothelial glycocalyx given that ROS cleave and destabilize the glycocalyx structure (Sieve et al., 2018).

MMPs modify the constituents of glycocalyx, thus disrupting glycocalyx in pathological conditions (Lipowsky, 2011). MMPs can cleave the protein core of syndecan, promoting shedding of the syndecan family and consequent thrombosis, destabilization of vascular walls, endothelial dysfunction, and inflammation (Fitzgerald et al., 2000; Chen et al., 2017). In addition, MMP-2 was associated to direct chondroitin sulfate cleavage (Hsu et al., 2006), while MMP-7 was responsible for cleavage of perlecain and heparan sulfate proteoglycans (Grindel et al., 2014) and MMP-9 mediated disruption of syndecan-4 (Ramnath et al., 2014). ROS also decrease the levels of the tissue inhibitors of metalloproteinases (TIMPs), thereby increasing the activity of MMPs (Siwik and Colucci, 2004). The inhibition of MMPs was able to restore the shedding of syndecan-4 in early diabetic disease (Ramnath et al., 2020).

Heparanase is an endoglycosidase that cleaves the side chains of heparan sulfate present in the syndecan and glypician families through hydrolysis, to disrupt glycocalyx (Garsen et al., 2014). Degradation of heparan sulfate reduces extracellular SOD (ecSOD), which remains attached to the heparan sulfate portion. ecSOD protects vascular cells from oxidative stress and its overexpression can attenuate heparanase expression, which suggests a prophylactic effect to prevent glycocalyx degradation (Kumagai et al., 2009).

Hyaluronidase degrades hyaluronic acid into fragments via hydrolysis of the disaccharides at hexosaminidic β(1-4) linkages (Wang et al., 2020). In addition, hyaluronic acid degradation products can produce ROS, which triggers several vascular disease processes (Soltés et al., 2006). Moreover,
other ROS derived from $\mathrm{O}_2^-$ and nitrogen monoxide (NO), including $\mathrm{H}_2\mathrm{O}_2$, $\mathrm{ONOO}^-$, and hypochlorous acid (Uchiyama et al., 1990).

ALTERNATIONS IN CAVEOLAR FUNCTION AND GLYCOCALYX IN ATHEROSCLEROSIS AND HYPERTENSION

Atherosclerosis and hypertension are multifactorial diseases. Atherosclerosis and its consequences represent the major cause of cardiovascular mortality. This disease is characterized by endothelial dysfunction, increased platelet adhesion, leukocyte recruitment, and accumulation of lipoproteins that evade phagocytosis (Eckardt et al., 2019). Endothelial dysfunction in the areas where atherosclerosis develops occurs through entry of lipoproteins, which is followed by lesions, leading to production of proinflammatory cytokines, migration of monocytes, and accumulation of macrophages (Gimbrone and Garcia-Cardeña, 2016). In turn, hypertension is a multifactorial disease that is associated with endothelial dysfunction, exacerbated oxidative stress, and inflammation in blood vessels (Dharmashankar and Widlansky, 2010). ECs play a pivotal role in vessel balance and pathophysiological conditions because they are exposed to inflammatory mediators that can impair or even destroy the endothelial layer and its components.

Caveolae and Cav-1 seem to play a part in atherosclerosis development. Numerous athrogenic proteins colocalize with caveolae in ECs, and caveolae are involved with transcytosis of low-density lipoprotein (LDL) particles (Frank et al., 2004; Sowa, 2012). Additionally, Cav-1 protein seems to have an atherosclerotic role. First, Cav-1 overexpression in ECs can increase atherosclerosis progression in apolipoprotein E-deficient mice (Fernández-Hernando et al., 2010). Moreover, the absence of Cav-1 promotes atheroprotection in vessels of Cav-1 knockout mice (Zhang et al., 2020). As proposed by Zhang et al. (2020), activation of endothelial autophagy by Cav-1 deficiency protects against atherosclerosis progression. In brief, autophagy is described as an evolutionarily conserved subcellular process that mediates degradation of proteins and damaged organelles via lysosomes (Mizushima and Komatsu, 2011).

As reported by Milovanova et al. (2008), apart from modulating NO production by eNOS, Cav-1 can modulate ROS production by NOX. In pulmonary hypertension, Cav-1 is a negative regulator of ROS derived from NO since lack of Cav-1 expression in pulmonary hypertension increases NOX activity and enhances ROS production (Chen et al., 2014). Furthermore, Cav-1 deletion prevents transactivation of hypertensive vascular remodeling and contributes to increased mitochondrial ROS levels in a model of AngII-induced hypertension (Forrester et al., 2017). On the other hand, lipid rafts and caveolae structural disruption with cholesterol disassembly drugs, increased ROS production in a different way than NOX. Recently, we have shown that caveolar structural disruption with methyl-β-cyclodextrin uncouples eNOS and raises ROS levels in Wistar normotensive rats and SHR aortas and mesenteric arteries (Potje et al., 2019). Besides that, the number of caveolae is reduced in renal hypertensive (2K-1C) and SHR rats as compared to normotensive rats, which impairs acetylcholine-induced endothelium-dependent relaxation and NO production (Rodrigues et al., 2010; Potje et al., 2019). The smaller number of caveolae could account for impaired NO donor-induced relaxation in 2K-1C rat aortas as compared to normotensive rat aortas (Rodrigues et al., 2007).

The literature contains controversial data about the role that Cav-1 has in the determination of arterial pressure. Whereas several authors do not report increased arterial pressure in Cav-1 knockout mice as compared to control wild-type (WT) mice, other authors describe lower arterial pressure in Cav-1 knockout mice than in WT mice (for a review, see Rahman and Sward, 2009). Cav-1 knockout mice present increased circulating NO levels and vasodilation, but the arterial pressure values measured by telemetry in awake mice and WT mice are similar (Desjardins et al., 2008). As proposed by Insel and Patel (2007), chronic Cav-1 deficiency could be compensated by other vascular mechanisms, to maintain the arterial pressure. Also, eNOS could be uncoupled in hypertensive vessels.

In physiological conditions, arterial ECs submitted to uniform flow (UF) release NO constantly (Noris et al., 1995). As described by Eckardt et al. (2019), the pathogenesis of atherosclerosis is associated with alterations in vascular glycocalyx. Glycocalyx degradation stimulates lipid flux, increasing lipid deposition in the arterial walls. This is associated with reduced eNOS expression, which decreases NO production and impairs vasodilation (Mitra et al., 2017). In addition, in most cases of atherosclerosis, plaques appear in the carotid bifurcation and aortic arch, which are regions with DF (Gimbrone and Garcia-Cardeña, 2013), thereby suggesting a relationship between hemodynamics and atherosclerosis progression. Cav-1 expression is reduced in DF as compared to UF, which indicates that Cav-1 regulation depends on the flow (Harding et al., 2018). Furthermore, as described by Harding et al. (2018), expression of active eNOS phosphorylated at Ser1177 is 50% lower in DF aortic arch than in UF abdominal aorta.

In this way, caveolae, Cav-1, and glycocalyx play an important role in vascular homeostasis, contributing to adequate NO production. However, atherosclerosis and hypertension impair NO bioavailability due to lower eNOS expression, eNOS inactivation, changes in Cav-1 expression or NOX4 activity, and eNOS uncoupling, leading to deleterious ROS overproduction.

DISCUSSION

In this review, we discuss recent findings about the physiological role of glycocalyx and caveolae, to maintenance of vascular tone, as well as alterations in these structures that are associated with the development of atherosclerosis and hypertension.
Even the glyocalyx has been reported as the primary sensor to mechanotransduction, a study demonstrated that caveolae show a unique molecular topography (Schnitzer et al., 1995) and may act as either mechano-sensors or transducers (Uittenbogaard et al., 2000; Gratton et al., 2004). Therefore, it could exist a relationship between glyocalyx and caveolae that is sensitive to feel mechanical forces and start the mechanotransduction process, and to promote an effective control of vascular tone.

During the first 30 min of exposition to shear stress, aortic and vein ECs (BAEC, bovine aortic EC; HUVEC, human umbilical vein EC) presented an accumulation of heparan sulfate and glypican-1 in the cell junctions. In contrast, there were no movement from chondroitin sulfate, syndecan-1, and Cav-1, indicating that these components and particularly the caveolae structure are anchored sufficiently to resist against initial exposure to shear stress (Zeng et al., 2013). On the other hand, the chronic shear stress (6 h) stimulated by changes in flow intensity in perfused lung microvessels was able to increase fivefold Cav-1 expression and sixfold caveolae density at the luminal surface compared with no-flow control, which contributed to enhanced mechano-sensitivity in cultured ECs (Rizzo et al., 2003). Moreover, the glypican-1 inhibition, but not syndecan-1, blocked eNOS activation induced by shear stress in mammalian epithelial cells (Ebong et al., 2014). These studies clarify the activation of glypican-1-caveolae-eNOS-NO pathway under mechanical stimulus. In this way, there is a relationship between glyocalyx and caveolae, where they are exchanging information all the time, and both are susceptible to reorganization underlie different stimulus to regulate vascular tone and promote vascular homeostasis.

Furthermore, the relationship between glyocalyx and caveolae is not only observed during shear stress and mechano-transduction. Catestatin is a peptide derived from glycoprotein chromogranin A, which is expressed in neuroendocrine and cardiac cells. Catestatin acts in several organs/systems, including the cardiovascular system. The catestatin was applied to BAECs, where it co-localizes with heparan sulfate proteoglycans, promoting endocytosis of caveolae and inducing Cav-1 internalization, followed by eNOS phosphorylation at Serine1179 (Fornero et al., 2014). Therefore, the glyocalyx and caveolae collaborate with each other during the catestatin-dependent eNOS-activation.

Glyocalyx contributes to maintaining vascular homeostasis, and it protects the EC surface. Thus, its disruption and shedding contribute to the development of cardiovascular diseases. Therefore, preventing its degradation is important. In a review, Becker et al. (2010) brought together the pharmacological options to avoid glyocalyx shedding and perturbation, which included hydrocortisone application, use of antithrombin III, and infusion of human plasma albumin, which seems to be the effective treatment. Apart from that, rat fat pad ECs supplemented with heparan sulfate or sphingosine 1-phosphate regenerate glyocalyx (Mensah et al., 2017). Another agent, sulodexide, which is a mixture of heparan sulfate and dermatan sulfate (Coccheri and Mannello, 2013), also reconstitutes glyocalyx in patients (Broekhuizen et al., 2010). Nuclear magnetic resonance analysis demonstrated that Krüppel-like Factor 2 (KLF2) inhibits endothelial glycosylation and contributes to hexosamine and glucuronic acid biosynthesis (Wang et al., 2020). In addition, inflammatory cytokines like TNF-α, interleukin-1β, interleukin-6, and interleukin-8, as well as ROS can activate heparanase, MMPs, and hyaluronidase, which are enzymes that cleave chains of glyocalyx constituents (Uchimido et al., 2019). Hence, antioxidant drugs and direct inhibition of cytokines may be another option to prevent glyocalyx degradation.

In the last 20 years, many studies have evidenced the relevance of caveolins by using Cav-1 knockout mice with cardiovascular abnormalities (Li et al., 2005; Lian et al., 2019). As suggested by Forrester et al. (2017), Cav-1 may be the therapeutic target to treat hypertension and atherosclerosis. However, the role of Cav-1 is controversial in the literature. It has dual action: Cav-1 impairs vascular functions in specific cases and at the same time, it seems to be essential to maintain vascular homeostasis. Hypertension induced by AngII in Cav-1 knockout mice does not develop vascular remodeling, which means that Cav-1 deletion attenuates vascular hypertrophy and perivascular fibrosis (Forrester et al., 2017). On the other hand, on the basis of the mouse hypoxia model, reduced Cav-1 expression increases ROS production, and macrophages isolated from Cav-1 knockout mice and Cav-1 knockdown siRNA in human lung fibroblasts enhances ROS production. The absence of Cav-1 negatively regulates NOX-mediated ROS production (Chen et al., 2014). Additionally, Cav1-deficient mice exhibit pulmonary hypertension, impairment of left ventricular diastolic function, increased pulmonary vascular remodeling, and right ventricle hypertrophy and decreased contractility (Zhao et al., 2002). Furthermore, the lack of Cav-1 improves NO-dependent vascular function and produces higher levels of NO (Drab et al., 2001; Razani et al., 2001; Murata et al., 2007), which suggests that Cav-1 impairs vascular function and contributes to the development of cardiovascular diseases. Notwithstanding, various studies have shown that the presence of Cav-1 is mandatory for eNOS activation (Chen et al., 2012).

Navarro et al. (2014) suggested gene or cell therapy as antisense and siRNA approaches to target Cav-1 directly or to modulate caveolar and lipid levels as an alternative intervention either to increase or to decrease Cav-1 expression. Moreover, activation of some GPCRs would allow to control or to re-program Cav-1 expression levels to explore therapeutic outcomes in cardiovascular diseases. Besides, the pathway glypican-1/caveolin-1/eNOS/NO should be better explored for better understanding of this path and possible therapeutic treatments.

CONCLUSION

The structure and function of both glyocalyx and caveolae are essential for maintenance of vascular homeostasis. Under
pathological conditions, that are associated with ROS synthesis and release, the glycocalyx and caveole structure and function could change, leading to impairment of their physiological function, which are the hallmark of cardiovascular diseases (see Figure 1).

AUTHOR CONTRIBUTIONS
SRP and LMB conceived the original scope of this manuscript. SRP, TP, MP, and LMB wrote specific sections. TP made the schematic representation of Figure 1. SRP and LMB critically reviewed and revised the final manuscript. All the authors have equally made a substantial intellectual contribution to this work in organizing and writing the manuscript, and all of them have approved it for submission.

REFERENCES
Abramsson, A., Kurup, S., Busse, M., Yamada, S., Lindblom, P., Schallmeiner, E., et al. (2007). Defective N-sulfation of heparan sulfate proteoglycans limits PDGF-BB binding and pericyte recruitment in vascular development. Genes Dev. 21, 316–331. doi: 10.1101/gad.398207
Agarwal, G., Krishnan, V. K., Prasad, S. B., Bhaduri, A., and Jayaraman, G. (2019). Biosynthesis of hyaluronic acid polymer: dissecting the role of sub structural elements of hyaluronan synthase. Sci. Rep. 9:12510. doi: 10.1038/s41598-019-48878-8
Allen, J. A., Halverson-Tamboli, R. A., and Rasenick, M. M. (2007). Lapid raft microdomains and neurotransmitter signalling. Nat. Rev. Neurosci. 8, 128–140. doi: 10.1038/nrn2059
Alphonson, S. C., and Rodseth, R. N. (2014). The endothelial glycocalyx: a review of the vascular barrier. Anesth. Analg. 69, 777–784. doi: 10.1111/anac.12661
Amaral, J. H., Ferreira, G. C., Pinheiro, L. C., Montenegro, M. F., and Tanus-Santos, J. E. (2015). Consistent antioxidant and anti-inflammatory effects of oral sodium nitrite in DOCA-salt hypertension. Redox Biol. 5, 340–346. doi: 10.1016/j.redox.2015.06.009
Anderson, R. G. (1998). The caveolae membrane system. Annu. Rev. Biochem. 67, 199–225. doi: 10.1146/annurev.biochem.67.1.199
Bartsch, A. M. W., Mathews, R., and Tarbell, J. M. (2017). Endothelial glycocalyx-mediated nitric oxide production in response to selective AFM pulling. Biophys. J. 113, 101–108. doi: 10.1016/j.bpj.2017.05.033
Baztani, M., Liu, L., Hill, M. M., Jedrychowski, M. P., Nixon, S. J., Lo, H. P., et al. (2009). MURC/cavin-4 and cavin family members form tissue-specific caveolar complexes. J. Cell Biol. 185, 1259–1273. doi: 10.1083/jcb.200903053
Bauman, A. L., Soughayer, J., Nguyen, B. T., Willoughby, D., Carnegie, G. K., Wong, W., et al. (2006). Dynamic regulation of cAMP synthesis through anchored PKA-adenyl cycle V/V1 complexes. Mol. Cell. 25, 925–931. doi: 10.1016/j.molcel.2006.07.025
Becker, B. F., Chappell, D., Bruegger, D., Annecke, T., and Jacob, M. (2010). Therapeutic strategies targeting the endothelial glycocalyx: acute deficits, but great potential. Cardiovasc. Res. 87, 300–310. doi: 10.1093/cvr/cqv137
Bernatchez, P., Sharma, A., Bauer, P. M., Marin, E., and Sessa, W. C. (2011). A noninhibitory mutant of the caveolin-1 scaffolding domain enhances eNOS-derived NO synthesis and vasodilation in mice. J. Clin. Invest. 121, 3747–3755. doi: 10.1172/JCI44778
Bernatchez, P. N., Bauer, P. M., Yu, J., Prendergast, J. S., He, P., and Sessa, W. C. (2005). Dissecting the molecular control of endothelial NO synthase by caveolin-1 using cell permeable peptides. Proc. Natl. Acad. Sci. U.S.A. 102, 761–766. doi: 10.1073/pnas.040224102
Bieberich, E. (2018). Sphingolipids and lipid rafts: novel concepts and methods of analysis. Chem. Phys. Lipids 216, 114–131. doi: 10.1016/j.chemphysilip.2018.08.003
Birben, E., Sahiner, U. M., Sackesen, C., Erzurum, S., and Kalayci, O. (2012). Oxidative stress and antioxidant defense. World Allergy Organ. J. 5, 9–19. doi: 10.1097/WOX.0b013e3182439613
Broekhuizen, L. N., Lemkes, B. A., Moonj, H. L., Meuwese, M. C., Verberne, H., Holleman, F., et al. (2010). Effect of sulodexide on endothelial glycocalyx and vascular permeability in patients with type 2 diabetes mellitus. Diabetologia 53, 2646–2655. doi: 10.1007/s00125-010-1916-x
Bucci, M., Gratton, J. P., Rudic, R. D., Acevedo, L., Rovieszko, F., Cirino, G., et al. (2006). In vivo delivery of the caveolin-1 scaffolding domain inhibits nitric oxide synthesis and reduces inflammation. Nat. Med. 6, 1362–1367. doi: 10.1038/s12176
Burtenshaw, D., Kitching, M., Redmond, E. M., Megason, I. L., and Cahill, P. A. (2019). Reactive oxygen species (ROS), intimal thickening, and subclinical atherosclerotic disease. Front. Cardiovasc. Med. 6:89. doi: 10.3389/fcvm.2019.00089
Cahill, P. A., and Redmond, E. M. (2016). Vascular endothelium – Gatekeeper of vessel health. Atherosclerosis 248, 97–109. doi: 10.1016/j.atherosclerosis.2016.03.007
Camargo, L. L., Harvey, A. P., Rios, F. J., Tsiroupolou, S., Da Silva, R. N. O., Cao, Z., et al. (2018). Vascular Nox (NADPH Oxidase) compartmentalization, protein hyperoxidation, and endoplasmic reticulum stress response in hypertension. Hypertension 72, 235–246. doi: 10.1161/HYPERTENSIONAHA.118.108242
Castro, M. M., Rizzi, E., Ceron, C. S., Guimaraes, D. A., Rodrigues, G. J., Bendhack, L. M., et al. (2012). Doxycycline ameliorates 2K-1C hypertension-induced vascular dysfunction in rats by attenuating oxidative stress and improving nitric oxide bioavailability. Nitric Oxide 26, 162–168. doi: 10.1016/j.niox.2012.01.009
Chen, E., Stringer, S. E., Rusch, M. A., Selleck, S. B., and Ekker, S. C. (2005). A unique role for 6-O sulfation modification in zebrafish vascular development. Dev. Biol. 284, 364–376. doi: 10.1016/j.ydbio.2005.03.032
Chen, F., Barman, S., Yu, Y., Haigh, S., Wang, Y., Black, S. M., et al. (2014). Caveolin-1 is a negative regulator of NADPH oxidase-derived reactive oxygen species. Free Rad. Biol. Med. 73, 201–213. doi: 10.1016/j.freeradbiomed.2014.04.029
Chen, Y., Peng, W., Raffetto, J. D., and Khalil, R. A. (2017). Matrix metalloproteinases in remodeling of lower extremity veins and chronic venous disease. Prog. Mol. Biol. Transl. Sci. 147, 267–299. doi: 10.1016/bx.pmsbs.2017.02.003
Chen, Z., Bakhshi, F. R., Shahajan, A. N., Sharma, T., Mao, M., Trane, A., et al. (2012). Nitric oxide-dependent Src activation and resultant caveolin-1 phosphorylation promote eNOS/caveolin-1 binding and eNOS inhibition. Mol. Biol. Cell 23, 1388–1398. doi: 10.1091/mbc.e11-09-0811
Chini, B., and Parenti, M. (2004). G-protein coupled receptors in lipid rafts and caveolae: how, when and why do they go there? J. Mol. Endocrinol. 32, 325–338. doi: 10.1677/jme.0.0320325
Coccheri, S., and Mannello, F. (2013). Development and use of sulodexide in vascular diseases: implications for treatment. Drug Des. Devel. Ther. 8, 49–65. doi: 10.2147/DDDT.S6762
Constantinescu, A. A., Vink, H., and Spanj, J. A. (2003). Endothelial cell glycocalyx modulates immobilization of leukocytes at the endothelial surface. Arterioscler. Thromb. Vasc. Biol. 23, 1541–1547. doi: 10.1161/01.ATV.0000085630.24353.3D
Czikora, I., Feher, A., Lucas, R., Fulton, D. J., and Bagi, Z. (2015). Caveolin-1 prevents sustained angiotension II-induced resistance artery constriction and
obesity-induced high blood pressure. *Am. J. Physiol Heart Circ. Physiol.* 308, H376–H385. doi: 10.1152/ajpheart.00649.2014

Dabagh, M., Jalali, P., Butler, P. J., Randles, A., and Tarbell, J. M. (2017). Mechanotransduction in endothelial cells subjected to oscillatory and multidirectional shear flow. *J. R. Soc. Interface* 14:20170185. doi: 10.1098/rsif.2017.0185

Desjardins, L., Lobysheva, I., Petal, M., Gallez, B., Feron, O., Desy, C., et al. (2008). Control of blood pressure variability in caveolin-1-deficient mice: role of nitric oxide identified in vivo through spectral analysis. *Cardiovasc. Res.* 79, 527–536. doi: 10.1093/cvr/cvn080

Dharmashankar, K., and Widiyantri, M. E. (2010). Vascular endothelial function and hypertension: insights and directions. *Curr. Hypertens. Rep.* 12, 448–455. doi: 10.1007/s11956-010-0150-2

Drab, M., Verkade, P., Elger, M., Kasper, M., Lohn, M., Lauterbach, B., et al. (2001). Loss of caveolea, vascular dysfunction, and pulmonary defects in caveolin-1 gene-deferred mice. *Science* 293, 2449–2452. doi: 10.1126/science.1062688

Dragovich, M. A., Chester, D., Fu, B. M., Wu, C., Xu, Y., Goligorsky, M. S., Dharmashankar, K., and Widlansky, M. E. (2010). Vascular endothelial function and the pathobiology of atherosclerosis. *Circ. Res.* 108, 620–636. doi: 10.1161/01.ATV.0000363061.83993.6b

González-Pacheco, F. R., Deudero, J. J., Castellanos, M. C., Castilla, M. A., Alvarez-Arroyo, M. V., Yagüe, S., et al. (2006). Mechanisms of endothelial response to oxidative aggression: protective role of autologous VEGF and induction of VEGFR2 by H2O2. *Am. J. Physiol. Heart Circ. Physiol.* 291, H1395–H1401. doi: 10.1152/ajpheart.01277.2005

Gratton, M. E., Potje, S. R., Troiano, J. A., Vale, G. T., Perassa, L. A., Nakamune, A. C. M. S., et al. (2019). Apocynin alters redox signaling in conductance and resistance vessels of spontaneously hypertensive rats. *Free Rad. Biol. Med.* 134, 53–63. doi: 10.1016/j.freeradbiomed.2018.12.026

Gratton, J. P., Bernatchez, P., and Sessa, W. C. (2004). Caveolea and caveolins in the cardiovascular system. *Circ. Res.* 94, 1408–1417. doi: 10.1161/01.RES.0000129178.56294.17

Grayson, T. H., Chadha, P. S., Bertrand, P. P., Chen, H., Morris, M. J., Senadheera, S., et al. (2012). Increased caveolea density and caveolin-1 expression accompany impaired NO-mediated vasorelaxation in diet-induced obesity. *Histochem. Cell Biol.* 139, 309–321. doi: 10.1007/s00418-012-1032-2

Hansen, C. G., Howard, G., and Nichols, B. J. (2011). Pacsin 2 is recruited to caveolae and functions in caveolar biogenesis. *J. Cell Sci.* 124(Pt 16), 2777–2785. doi: 10.1242/jcs.084319

Harcourt, C., Hidayat, R., Mensah, S. A., Herzig, T. H., and Potje, S. R. (2018). Pro-atherosclerotic disturbed flow disrupts caveolin-1 expression, localization, and function via glyocalyx degradation. *J. Transl. Med.* 16:364. doi: 10.1186/s12967-018-1721-2

Hayer, A., Stoeber, M., Bissig, C., and Helenius, A. (2010). Biogenesis of caveolae: caveolae, and endothelial cell function. *Frontiers in Physiology* | www.frontiersin.org 10 January 2021 Volume 11 Article 620840

Fuster, M., and Wang, L. (2010). Endothelial heparan sulfate in angiogenesis. *Prog Mol. Biol. Transl. Sci.* 93, 179–212. doi: 10.1016/S1877-1173(10)90039-9

Garsen, M., Rops, A. L., Rabelink, T. J., Berden, J. H., and van der Vlag, J. (2014). The role of heparanase and the endothelial glyocalyx in the development of proteinuria. *Nephrol. Dial. Transplant.* 29, 49–55. doi: 10.1093/ndt/gft010

Gill-Lindsay, J., and González-Vázquez, C. (2005). Characterization of four different effects elicited by H2O2 in rat aorta. *Vasc. Pharmacol.* 43, 128–138. doi: 10.1016/j.vph.2005.06.001

Gimbrone, M. A. Jr., and Garcia-Cardeña, G. (2013). Vascular endothelium, hemodynamics, and the pathobiology of atherosclerosis. *Cardiovasc. Pathol.* 22, 9–15. doi: 10.1016/j.carpath.2012.06.006

Gimbrone, M. A. Jr., and Garcia-Cardeña, G. (2016). Endothelial cell dysfunction and the pathobiology of atherosclerosis. *Circ. Res.* 118, 620–636. doi: 10.1161/CIRCRESAHA.115.306301

Insel, P. A., and Patel, H. H. (2007). Do studies in caveolin-1 knockouts teach us about physiology and pharmacology or instead, the ways mice compensate the “lost proteins”? *Br. J. Pharmacol.* 150, 251–254. doi: 10.1038/bjp.0706981

Potje et al. Glycocalyx and Caveolae on Vascular Tone Control
Sena, C. M., Leandro, A., Azul, L., Seica, R., and Perry, G. (2018). Vascular oxidative stress: impact and therapeutic approaches. *Front. Physiol.* 9:1668. doi: 10.3389/fphys.2018.01668

Sessa, W. C. (2004). ENOS at a glance. *J. Cell. Sci.* 117(Pt 12), 2427–2429. doi: 10.1242/jcs.011655

Shaul, P. W. (2003). Endothelial nitric oxide synthase, caveolea and the development of atherosclerosis. *J. Physiol.* 547(Pt 1), 21–33. doi: 10.1113/jphysiol.2002.031534

Shaw, L., Sweeney, M. A., O’Neill, S. C., Jones, C. J. P., Austin, C., and Taggart, M. J. (2006). Caveolea and sarcoplasmatic reticular coupling in smooth muscle cells of pressurized arteries: the relevance for Ca²⁺ oscillations and tone. *Cardiovasc. Res.* 69, 825–835. doi: 10.1016/j.cardiores.2005.12.016

Shimada, K., Kobayashi, M., Kimura, S., Nishinaga, M., Takeuchi, K., and Ozawa, T. (1991). Anticoagulant heparin-like glycosaminoglycans on endothelial cell surface. *Jpn. Circ. J.* 55, 1016–1021. doi: 10.1253/jcn.55.1016

Sieve, I., Münster-Kühnel, A. K., and Hilfiker-Kleiner, D. (2018). Regulation and function of endothelial glycoalyx layer in vascular diseases. *Vasc. Pharmacol.* 100, 26–33. doi: 10.1016/j.vph.2017.09.002

Siva, B. R., Pernomian, L., Grando, M. D., Amaral, J. H., Tanus-Santos, J. E., and Bendhak, L. M. (2013). Hydrogen peroxide modulates phenylephrine-induced contractile response in renal hypertensive rat aorta. *Eur. J. Pharmacol.* 721, 193–200. doi: 10.1016/j.ejphar.2013.09.036

Siwik, D. A., and Colucci, W. S. (2004). Regulation of matrix metalloproteinases by cytokines and reactive oxygen/nitrogen species in the myocardium. *Heart Fail. Rev.* 9, 43–51. doi: 10.1007/BF00001393.40674.13

Soltész, L., Mendichi, R., Kogan, G., Schiller, J., Stankovska, M., and Arnhold, J. (2006). Degradative action of reactive oxygen species on hyaluronan. *Biomacromolecules* 7, 659–668. doi: 10.1021/bm050867v

Sowa, G. (2012). Caveolea, caveolins, cavins, and endothelial cell function: new insights. *Front. Physiol.* 2:120. doi: 10.3389/fphys.2011.00120

Stenzel, D., Nye, E., Nisancioglu, M., Adams, R. H., Yamaguchi, Y., and Gerhardt, H. (2009). Peripheral mural cell recruitment requires cell-autonomous heparan sulfate. *Blood* 114, 915–924. doi: 10.1182/blood-2008-10-186239

Stoiber, M., Stocke, I. K., Hanni, C., Bleck, C. K. E., Balsi, G., and Helenius, A. (2012). Oligomers of the ATPase EHD2 confine caveolea to the plasma membrane through association with actin. *EMBO J.* 31, 2350–2364. doi: 10.1038/emboj.2012.98

Thi, M. M., Tarbel, J. M, Weinbaum, S., and Spray, D. C. (2004). The role of the glycoalyx in reorganization of the actin cytoskeleton under fluid shear stress: a “bumper-car” model. *Proc. Natl. Acad. Sci. U.S.A.* 101, 16483–16488. doi: 10.1073/pnas.0407474101

Tovar, A. M., de Mattos, D. A., Stelling, M. P., Sarcinelli-Luz, B. S., Nazareth, R. A., and Mourão, P. A. (2005). Dermatan sulfate is the predominant antithrombotic glycosaminoglycan in vessel walls: implications for a possible physiological function of heparin cofactor II. *Biochim. Biophys. Acta.* 1740, 45–53. doi: 10.1016/j.bbadis.2005.02.008

Tsai, M. H., and Jiang, M. J. (2010). Reactive oxygen species are involved in regulating alpha1-adrenoceptor-activated vascular smooth muscle contraction. *J. Biomed. Sci.* 17:67. doi: 10.1186/1423-0127-17-67

Uchimido, R., Schmidt, E. P., and Shapira, N. I. (2019). The glycoalyx: a novel diagnostic and therapeutic target in sepsis. *Crit. Care* 23:16. doi: 10.1186/s13054-018-2292-6

Uchiyama, H., Dobashi, Y., Ohkouchi, K., and Nagasawa, K. (1990). Chemical change involved in the oxidative reductive depolymerization of hyaluronic acid. *J. Biol. Chem.* 265, 7753–7759.

Uittenbogaard, A., Shaul, P. W., Yuhanna, I. S., Blair, A., and Smart, E. J. (2000). High density lipoprotein prevents oxidized low density lipoprotein-induced inhibition of endothelial nitric-oxide synthase localization and activation in caveolea. *J. Biol. Chem.* 275, 11278–11283. doi: 10.1074/jbc.275.15.11278

Ungvari, Z., Czatsar, A., Huang, A., Kaminski, P. M., Wolin, M. S., and Koller, A. (2003). High pressure induces superoxide production in isolated arteries via protein kinase C-dependent activation of NAD(P)H oxidase. *Circulation* 108, 1253–1258. doi: 10.1161/01.CIR.0000079165.84309.4D

Vanhoucke, P. M., Shimokawa, H., Félotou, M., and Tang, E. H. C. (2017). Endothelial dysfunction and vascular disease – a 30th anniversary update. *Acta Physiol.* 219, 22–96. doi: 10.1111/apha.12646

Potje et al. Glycoalyx and Caveolea on Vascular Tone Control
Vara, D., and Pula, G. (2014). Reactive oxygen species: physiological roles in the regulation of vascular cells. *Curr. Mol. Med.* 14, 1103–1125. doi: 10.2174/15665240146661006314010

Vogel, E. R., Manlove, L. J., Kuipers, I., Thompson, M. A., Fang, Y. H., Freeman, M. R., et al. (2019). Caveolin-1 scaffolding domain peptide prevents hyperoxia-induced airway remodeling in a neonatal mouse model. *Am. J. Physiol. Lung Cell. Mol. Physiol.* 317, L19–L108. doi: 10.1152/ajplung.00111.2018

Volonte, D., Liu, Z., Musile, P. M., Stoppani, E., Wakabayashi, N., Di, Y. P., et al. (2013). Inhibition of nuclear factor-erythroid 2-related factor (Nrf2) by caveolin-1 promotes stress-induced premature senescence. *Mol. Biol. Cell.* 24, 1852–1862. doi: 10.1091/mbc.E12-09-0666

Wanaski, S. P., Ng, B. K., and Glaser, M. (2003). Caveolin scaffolding region and the membrane binding region of SRC form lateral membrane domains. *Biochemistry* 42, 42–56. doi: 10.1021/bi012097n

Wang, G., Kostidis, S., Tiemeier, G. L., Sol, W. M. P. J., de Vries, M. R., Giera, M., et al. (2020). Shear stress regulation of endothelial glycocalyx structure is determined by glucobiosynthesis. *Arterioscler. Thromb. Vasc. Biol.* 40, 350–364. doi: 10.1161/ATVBAHA.119.313399

Wang, X. L., Ye, D., Peterson, T. E., Cao, S., Shah, V. H., Katusic, Z. S., et al. (2005). Caveolae targeting and regulation of large conductance Ca(2+)-activated K+ channels in vascular endothelial cells. *J. Biol. Chem.* 280, 11656–11664. doi: 10.1074/jbc.M410987200

Wyse, B. D., Prior, I. A., Qian, H., Morrow, I. C., Nixon, S., Muncke, C., et al. (2003). Caveolin interacts with the angiotensin II type 1 receptor during exocytic transport but not at the plasma membrane. *J. Biol. Chem.* 278, 23738–23746. doi: 10.1074/jbc.M212892200

Yen, W., Cai, B., Yang, J., Zhang, L., Zeng, M., Tarbell, J. M., et al. (2015). Endothelial surface glycocalyx can regulate flow-induced nitric oxide production in microvessels in vivo. *PLoS One* 10:e0117133. doi: 10.1371/journal.pone.0117133

Zeng, Y., and Liu, J. (2016). Role of glypcian-1 in endothelial NOS activation under various steady shear stress magnitudes. *Exp. Cell Res.* 348, 184–189. doi: 10.1016/j.yexcr.2016.09.017

Zeng, Y., and Tarbell, J. M. (2014). The adaptive remodeling of endothelial glycocalyx in response to fluid shear stress. *PLoS One* 9:e86249. doi: 10.1371/journal.pone.0086249

Zeng, Y., Waters, M., Andrews, A., Honarmandi, P., Ebong, E. E., Rizzo, V., et al. (2013). Fluid shear stress induces the clustering of heparan sulfate via mobility of glypician-1 in lipid rafts. *Am. J. Physiol. Heart Circ. Physiol.* 305, H811–H820. doi: 10.1152/ajpheart.00764.2012

Zhang, X., Ramirez, C. M., Aryan, B., Madrigal-Matute, J., Liu, X., Diaz-A., et al. (2020). Cav-1 (Caveolin-1) deficiency increases autophagy in the endothelium and attenuates vascular inflammation and atherosclerosis. *Arterioscler. Thromb. Vasc. Biol.* 40, 1510–1522. doi: 10.1161/ATVBAHA.120.314291

Zhao, Y., Vanhoutte, P. M., and Leung, S. W. (2015). Vascular nitric oxide: beyond eNOS. *J. Pharmacol. Sci.* 129, 83–94. doi: 10.1016/j.jphs.2015.09.002

Zhao, Y. Y., Liu, Y., Stan, R. V., Fan, L., Gu, Y., Dalton, N., et al. (2002). Defects in caveolin-1 cause dilated cardiomyopathy and pulmonary hypertension in knockout mice. *Proc. Natl. Acad. Sci. U.S.A.* 99, 11375–11380. doi: 10.1073/pnas.172360799

Zhou, B., Qu, Y., Wu, N., Chen, A. D., Zhou, H., Chen, Q., et al. (2020). FNDCS5 attenuates oxidative stress and NLRP3 inflammasome activation in vascular smooth muscle cells via activating the AMPK-SIRT1 signal pathway. *Oxid. Med. Cell. Longev.* 2020:6384803. doi: 10.1155/2020/6384803

Zuo, L., Ushio-Fukai, M., Ikeda, S., Hilenski, L., Patrushev, N., and Alexander, R. W. (2005). Caveolin-1 is essential for activation of Rac1 and NAD(P)H oxidase after angiotensin II type 1 receptor stimulation in vascular smooth muscle cells: role in redox signaling and vascular hypertrophy. *Arterioscler. Thromb. Vasc. Biol.* 25, 1824–1830. doi: 10.1161/01.ATV.0000175295.09607.18

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 Potje, Paula, Paulo and Bendhack. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.